Ignite Creation Date:
2025-12-24 @ 6:28 PM
Ignite Modification Date:
2025-12-24 @ 6:28 PM
Study NCT ID:
NCT04202068
Status:
COMPLETED
Last Update Posted:
2019-12-17
First Post:
2019-12-11
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006069', 'term': 'Gonorrhea'}], 'ancestors': [{'id': 'D016870', 'term': 'Neisseriaceae Infections'}, {'id': 'D016905', 'term': 'Gram-Negative Bacterial Infections'}, {'id': 'D001424', 'term': 'Bacterial Infections'}, {'id': 'D001423', 'term': 'Bacterial Infections and Mycoses'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D015231', 'term': 'Sexually Transmitted Diseases, Bacterial'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D002443', 'term': 'Ceftriaxone'}, {'id': 'D013407', 'term': 'Sulbactam'}, {'id': 'D007267', 'term': 'Injections'}], 'ancestors': [{'id': 'D002439', 'term': 'Cefotaxime'}, {'id': 'D002505', 'term': 'Cephacetrile'}, {'id': 'D002511', 'term': 'Cephalosporins'}, {'id': 'D047090', 'term': 'beta-Lactams'}, {'id': 'D007769', 'term': 'Lactams'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D013843', 'term': 'Thiazines'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D010406', 'term': 'Penicillins'}, {'id': 'D004333', 'term': 'Drug Administration Routes'}, {'id': 'D004358', 'term': 'Drug Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Ceftriaxone sodium and Sulbactam Sodium for injection'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 113}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-07-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-12', 'completionDateStruct': {'date': '2016-05-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-12-15', 'studyFirstSubmitDate': '2019-12-11', 'studyFirstSubmitQcDate': '2019-12-15', 'lastUpdatePostDateStruct': {'date': '2019-12-17', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-12-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-05-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'bacterial eradicatio', 'timeFrame': 'Up to Day 8', 'description': 'Number of subjects with culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital site at the Test-of-Cure (TOC)'}], 'secondaryOutcomes': [{'measure': 'clinical cure', 'timeFrame': 'Up to Day 8', 'description': 'Number of subjects with disappearance of clinical symptoms and signs at the Test-of-Cure (TOC)'}, {'measure': 'Comprehensive curative effect', 'timeFrame': 'Up to Day 8', 'description': 'Number of subjects with culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital site and disappearance of clinical symptoms and signs'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Gonorrhea']}, 'descriptionModule': {'briefSummary': 'This is a phaseIV, multicenter, open-label，single arm study which will be performed to evaluate efficacy and safety of Ceftriaxone sodium and Sulbactam Sodium for injection for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae in adolescent and adult subjects.', 'detailedDescription': 'In this study, adults will be administered as one 3g IV dose at the study site,Children under 12 will be administered as one 75mg/kg IV dose . Approximately 100 subjects will be recruited to receive study treatment. The duration of the study will be approximately 14 days.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '6 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Subjects must be \\>=6 or ≦80 years of age at the time of signing the informed consent,both gender\n* Subjects having clinical suspicion of a urogenital gonococcal infection with or without gonococcal infection according to the laboratory test results of symptoms, physical symptoms, gonococcus smear, culture, etc.\n* Subjects having clinical suspicion of a gonococcal infection must have both of the following risk factors:once used three generations of cephalosporin invalid, and sensitive to this product (including gonorrhea urethritis, cervicitis, proctitis, pharyngitis).\n* Male and female subject must agree to use contraception (male condoms) during intercourse from the Baseline Visit through completion of the TOC Visit.\n\nExclusion Criteria:\n\n* Subject has a history of sensitivity to the study treatments, or components thereof, or a history of a drug (including erythromycin and any macrolide or ketolide drug) or other allergy that, in the opinion of the investigator or medical monitor, contraindicates his or her participation\n* Subject has received any cephalosporinl therapy for the treatment of a gonococcal infection\n* Pregnant or lactating women, or women Subject of childbearing age who were unwilling or unable to use acceptable methods of contraception throughout the study period.\n* Famale subject who were positive for pregnancy tests at the time of inclusion or before the start of study drug use.\n* Subject has risk of potentially serious drug interactions\n* Subject has major diseases such as cardiovascular disease, hepatorenal disease and mental disease, or other factors, the researcher should not participate in the study according to comprehensive judgment\n* Subject has a known history of alcohol or drug abuse\n* Subject has a known any complicated or systemic gonorrhea infection, such as pelvic inflammatory disease, arthritis, endocarditis'}, 'identificationModule': {'nctId': 'NCT04202068', 'acronym': 'CRO-SBT', 'briefTitle': 'A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea', 'organization': {'class': 'INDUSTRY', 'fullName': 'Xiangbei Welman Pharmaceutical Co., Ltd'}, 'officialTitle': 'A Study Evaluating Efficacy and Safety of Ceftriaxone Sodium and Sulbactam Sodium for Injection in the Treatment of Uncomplicated Urogenital Gonorrhea', 'orgStudyIdInfo': {'id': 'GC0048-015'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Ceftriaxone sodium and Sulbactam Sodium for injection', 'description': 'combinations of β-Lactamase inhibitors', 'interventionNames': ['Drug: Ceftriaxone sodium and Sulbactam Sodium for injection']}], 'interventions': [{'name': 'Ceftriaxone sodium and Sulbactam Sodium for injection', 'type': 'DRUG', 'otherNames': ['CRO-SBT'], 'description': 'Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.', 'armGroupLabels': ['Ceftriaxone sodium and Sulbactam Sodium for injection']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'pingyu P Zhou, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Shanghai Dermatology Hospital'}, {'name': 'shunming S Xu, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "People's Hospital of Shanghai Pudong New Area"}, {'name': 'yanyue Tong, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "People's Hospital of Quzhou"}, {'name': 'zhehu Jin, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The Affiliated Hospital of Yanbian University'}, {'name': 'bo Cheng, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'First Affiliated Hospital of Fujian Medical University'}, {'name': 'wuqing W Wang, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The Central Hospital of Shanghai Minhang District'}, {'name': 'ping Wang, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "The Third People's Hospital of Hangzhou"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Xiangbei Welman Pharmaceutical Co., Ltd', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}